GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » ROA %

Clal Biotechnology Industries (XTAE:CBI) ROA % : 0.00% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Clal Biotechnology Industries's annualized Net Income for the quarter that ended in Dec. 2023 was ₪0.00 Mil. Clal Biotechnology Industries's average Total Assets over the quarter that ended in Dec. 2023 was ₪176.69 Mil. Therefore, Clal Biotechnology Industries's annualized ROA % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Clal Biotechnology Industries's ROA % or its related term are showing as below:

XTAE:CBI' s ROA % Range Over the Past 10 Years
Min: -20.37   Med: -16.53   Max: 17.71
Current: -15.61

During the past 13 years, Clal Biotechnology Industries's highest ROA % was 17.71%. The lowest was -20.37%. And the median was -16.53%.

XTAE:CBI's ROA % is ranked better than
68.58% of 1550 companies
in the Biotechnology industry
Industry Median: -34.765 vs XTAE:CBI: -15.61

Clal Biotechnology Industries ROA % Historical Data

The historical data trend for Clal Biotechnology Industries's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries ROA % Chart

Clal Biotechnology Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.87 17.71 -16.92 -19.67 -18.21

Clal Biotechnology Industries Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.52 -27.24 -13.28 - -

Competitive Comparison of Clal Biotechnology Industries's ROA %

For the Biotechnology subindustry, Clal Biotechnology Industries's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clal Biotechnology Industries's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's ROA % distribution charts can be found below:

* The bar in red indicates where Clal Biotechnology Industries's ROA % falls into.



Clal Biotechnology Industries ROA % Calculation

Clal Biotechnology Industries's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-31.051/( (182.69+158.386)/ 2 )
=-31.051/170.538
=-18.21 %

Clal Biotechnology Industries's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (194.987+158.386)/ 2 )
=0/176.6865
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Clal Biotechnology Industries  (XTAE:CBI) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=0/176.6865
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0 / 0)*(0 / 176.6865)
=Net Margin %*Asset Turnover
=N/A %*0
=0.00 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Clal Biotechnology Industries ROA % Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries (XTAE:CBI) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries (XTAE:CBI) Headlines

From GuruFocus

Does the Increase in Volatility Signal a Dangerous Market Environment?

By Chuck Carnevale Chuck Carnevale 11-11-2016

Should We Devote Attention to Market Factors?

By Grahamites Grahamites 08-25-2015

This Warren Buffett Bargain Stock Is Good For A Double

By Jonathan Poland Jonathan Poland 05-27-2015

McDermott Announces Ethylene Furnace Award in Indonesia

By PRNewswire PRNewswire 01-24-2019

CBI: Former Buffett Stock Worth Buying Now

By Jonathan Poland Jonathan Poland 06-29-2017

Chairman, CEO, CFO Purchase Shares in McDermott

By PRNewswire PRNewswire 11-07-2018

Van Den Berg Almost Sells Out 4 Stakes in 1st Quarter

By David Goodloe David Goodloe 04-20-2016